a Global Phase 1b/2 Study evaluate the safety and early efficacy of etakafusp alfa in Combination with Rilvegostomig as a first-line treatment in combination with rilvegostomig in patients with advanced or metastatic NSCLC.
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs Etakafusp alfa (Primary) ; Rilvegostomig (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 15 Jan 2025 New trial record
- 07 Jan 2025 Asher Bio announced an agreement with AstraZeneca to supply etakafusp alfa (formerly known as AB248), to be evaluated in combination with rilvegostomig, in patients with advanced or metastatic NSCLC.